Details for New Drug Application (NDA): 216227
NDA 216227 describes IHEEZO, which is a drug marketed by Harrow Eye and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the IHEEZO profile page.
The generic ingredient in IHEEZO is chloroprocaine hydrochloride. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the chloroprocaine hydrochloride profile page.
The generic ingredient in IHEEZO is chloroprocaine hydrochloride. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the chloroprocaine hydrochloride profile page.
Summary for 216227
| Tradename: | IHEEZO |
| Applicant: | Harrow Eye |
| Ingredient: | chloroprocaine hydrochloride |
| Patents: | 2 |
Pharmacology for NDA: 216227
| Physiological Effect | Local Anesthesia |
Suppliers and Packaging for NDA: 216227
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| IHEEZO | chloroprocaine hydrochloride | GEL;OPHTHALMIC | 216227 | NDA | Harrow Eye, LLC | 82667-300 | 82667-300-00 | 1 POUCH in 1 CARTON (82667-300-00) / 1 VIAL in 1 POUCH / 800 mg in 1 VIAL |
| IHEEZO | chloroprocaine hydrochloride | GEL;OPHTHALMIC | 216227 | NDA | Harrow Eye, LLC | 82667-300 | 82667-300-01 | 1 POUCH in 1 CARTON (82667-300-01) / 1 VIAL in 1 POUCH / 800 mg in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | GEL;OPHTHALMIC | Strength | 3% | ||||
| Approval Date: | Sep 27, 2022 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Sep 15, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | METHOD OF INDUCING OCULAR ANESTHESIA | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | May 14, 2039 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
